Narrative Review of Targetable Features of Pediatric Acute Myeloid Leukemia from Molecular and Metabolic Perspectives

Overview

Journal Pediatr Med

Publisher AME Publishing Company

Date 2025 Jan 29

PMID 39877586

Authors

Adriana Milagros Trabal

Joya Chandra

Affiliations

Soon will be listed here.

Abstract

Background And Objective: Unlike the majority of pediatric leukemia patients, young patients with acute myeloid leukemia (AML) have not seen significant improvement in treatment outcomes. This is frequently attributed to the heterogeneity of this malignancy in terms of its mutations and molecularly defined categories. In adult versus pediatric cases of AML, the heterogeneity is preserved, although there are key differences in the incidence of gene mutations, chromosomal translocations, and other molecular features. Current treatment strategies consider broader cellular features of AML, such as altered metabolic and anti-apoptotic properties, and many of these are common across pediatric and adult AML.

Methods: A narrative review was conducted to compile literature regarding molecular and metabolic features of AML and new treatment modalities in the adult and pediatric population. Articles published in PubMed were gathered and studied over 6 months for review and comparison. Studies published in English over a ten-year period from 2000-2020 were included. Keywords used for the searches included acute myeloid leukemia, cytogenetics, pediatric acute myeloid leukemia, and treatment of acute myeloid leukemia.

Key Content And Findings: Molecular characteristics of adult-onset myeloid leukemia as compared to those in the pediatric population are detailed. We highlight unique features of pediatric AML biology and potential ties to metabolism, as well as recent advances in therapy.

Conclusions: Differences in adult and pediatric AML cytogenetics, metabolism, and molecular features should be further characterized in order to individualize treatment, develop new therapeutic options, and improve patient outcome.

References

Im H . Current treatment for pediatric acute myeloid leukemia. Blood Res. 2018; 53(1):1-2. PMC: 5898987. DOI: 10.5045/br.2018.53.1.1. View

Carter J, Hege K, Kalpage H, Edwards H, Huttemann M, Taub J . Targeting mitochondrial respiration for the treatment of acute myeloid leukemia. Biochem Pharmacol. 2020; 182:114253. PMC: 8073742. DOI: 10.1016/j.bcp.2020.114253. View

Bello C, Yu D, Komrokji R, Zhu W, Wetzstein G, List A . Outcomes after induction chemotherapy in patients with acute myeloid leukemia arising from myelodysplastic syndrome. Cancer. 2011; 117(7):1463-9. PMC: 4545502. DOI: 10.1002/cncr.25598. View

Grimwade D, Hills R, Moorman A, Walker H, Chatters S, Goldstone A . Refinement of cytogenetic classification in acute myeloid leukemia: determination of prognostic significance of rare recurring chromosomal abnormalities among 5876 younger adult patients treated in the United Kingdom Medical Research Council trials. Blood. 2010; 116(3):354-65. DOI: 10.1182/blood-2009-11-254441. View

Castaigne S, Pautas C, Terre C, Raffoux E, Bordessoule D, Bastie J . Effect of gemtuzumab ozogamicin on survival of adult patients with de-novo acute myeloid leukaemia (ALFA-0701): a randomised, open-label, phase 3 study. Lancet. 2012; 379(9825):1508-16. DOI: 10.1016/S0140-6736(12)60485-1. View

Rashkovan M, Ferrando A . Metabolic dependencies and vulnerabilities in leukemia. Genes Dev. 2019; 33(21-22):1460-1474. PMC: 6824464. DOI: 10.1101/gad.326470.119. View

McKenney A, Levine R . Isocitrate dehydrogenase mutations in leukemia. J Clin Invest. 2013; 123(9):3672-7. PMC: 3754251. DOI: 10.1172/JCI67266. View

Molina J, Sun Y, Protopopova M, Gera S, Bandi M, Bristow C . An inhibitor of oxidative phosphorylation exploits cancer vulnerability. Nat Med. 2018; 24(7):1036-1046. DOI: 10.1038/s41591-018-0052-4. View

Yip K, Reed J . Bcl-2 family proteins and cancer. Oncogene. 2008; 27(50):6398-406. DOI: 10.1038/onc.2008.307. View

10.

Daver N, Schlenk R, Russell N, Levis M . Targeting FLT3 mutations in AML: review of current knowledge and evidence. Leukemia. 2019; 33(2):299-312. PMC: 6365380. DOI: 10.1038/s41375-018-0357-9. View

11.

Zhou L, Wang Y, Zhou M, Zhang Y, Wang P, Li X . HOXA9 inhibits HIF-1α-mediated glycolysis through interacting with CRIP2 to repress cutaneous squamous cell carcinoma development. Nat Commun. 2018; 9(1):1480. PMC: 5902613. DOI: 10.1038/s41467-018-03914-5. View

12.

Gamis A, Alonzo T, Meshinchi S, Sung L, Gerbing R, Raimondi S . Gemtuzumab ozogamicin in children and adolescents with de novo acute myeloid leukemia improves event-free survival by reducing relapse risk: results from the randomized phase III Children’s Oncology Group trial AAML0531. J Clin Oncol. 2014; 32(27):3021-32. PMC: 4162498. DOI: 10.1200/JCO.2014.55.3628. View

13.

Andersson A, Miller D, Lynch J, Lemoff A, Cai Z, Pounds S . IDH1 and IDH2 mutations in pediatric acute leukemia. Leukemia. 2011; 25(10):1570-7. PMC: 3883450. DOI: 10.1038/leu.2011.133. View

14.

Alfayez M, Kantarjian H, Kadia T, Ravandi-Kashani F, Daver N . CPX-351 (vyxeos) in AML. Leuk Lymphoma. 2019; 61(2):288-297. DOI: 10.1080/10428194.2019.1660970. View

15.

Raffel S, Klimmeck D, Falcone M, Demir A, Pouya A, Zeisberger P . Quantitative proteomics reveals specific metabolic features of acute myeloid leukemia stem cells. Blood. 2020; 136(13):1507-1519. DOI: 10.1182/blood.2019003654. View

16.

Conneely S, Stevens A . Advances in Pediatric Acute Promyelocytic Leukemia. Children (Basel). 2020; 7(2). PMC: 7072343. DOI: 10.3390/children7020011. View

17.

Anselmi L, Bertuccio S, Lonetti A, Prete A, Masetti R, Pession A . Insights on the Interplay between Cells Metabolism and Signaling: A Therapeutic Perspective in Pediatric Acute Leukemias. Int J Mol Sci. 2020; 21(17). PMC: 7503381. DOI: 10.3390/ijms21176251. View

18.

Cluntun A, Lukey M, Cerione R, Locasale J . Glutamine Metabolism in Cancer: Understanding the Heterogeneity. Trends Cancer. 2017; 3(3):169-180. PMC: 5383348. DOI: 10.1016/j.trecan.2017.01.005. View

19.

Buelow D, Anderson J, Pounds S, Shi L, Lamba J, Hu S . DNA Methylation-Based Epigenetic Repression of SLC22A4 Promotes Resistance to Cytarabine in Acute Myeloid Leukemia. Clin Transl Sci. 2020; 14(1):137-142. PMC: 7877866. DOI: 10.1111/cts.12861. View

20.

Paul M, Mukhopadhyay A . Tyrosine kinase - Role and significance in Cancer. Int J Med Sci. 2005; 1(2):101-115. PMC: 1074718. DOI: 10.7150/ijms.1.101. View